Compare Grab Holdings Ltd. (GRAB) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Johnson & Johnson — how do they compare? Grab Holdings Ltd. trades at $3.18 (market cap $12.72B), while Johnson & Johnson trades at $260.9 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 48.6× Grab Holdings Ltd.'s market cap, and Johnson & Johnson pays a 2.09% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Johnson & Johnson for 129 Days on average.
| GRAB | JNJ | |
|---|---|---|
Market Cap | $12.72B | $618.09B |
Volume | 65,352,859 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $6.17 | $278.43 |
52-Week Low | $2.80 | $186.00 |
Typical Hold Time | 94 Days | 129 Days |
Enterprise Value | $8.46B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Grab Holdings (GRAB) trades at $3.195, up 3.73% today, showing strong momentum after recent volatility. The stock demonstrates improving fundamentals with revenue growing from $2.8B in 2024 to $3.37B in 2025 and achieving profitability with $268M net income. Recent Q2 2026 earnings beat expectations with $0.06 EPS versus $0.05 expected, while technical indicators show bearish signals despite neutral oscillators. The company's $1.49B acquisition of Atome Financial positions it for financial services expansion.
Grab presents a compelling turnaround story with accelerating revenue growth and recent profitability. The strong analyst consensus (91.67% buy ratings) and $30M CEO share purchase signal confidence, though technical weakness and competitive pressures in Southeast Asia's ride-hailing market warrant caution. Key catalysts include continued execution on profitability targets and successful integration of Atome acquisition.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
